These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. JAK2 Val617Phe activating tyrosine kinase mutation in juvenile myelomonocytic leukemia. Tono C; Xu G; Toki T; Takahashi Y; Sasaki S; Terui K; Ito E Leukemia; 2005 Oct; 19(10):1843-4. PubMed ID: 16079889 [No Abstract] [Full Text] [Related]
5. Mutational analysis in chronic myeloid leukemia: when and what to do? Branford S; Hughes TP Curr Opin Hematol; 2011 Mar; 18(2):111-6. PubMed ID: 21245758 [TBL] [Abstract][Full Text] [Related]
6. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line. Ricci C; Scappini B; Divoky V; Gatto S; Onida F; Verstovsek S; Kantarjian HM; Beran M Cancer Res; 2002 Nov; 62(21):5995-8. PubMed ID: 12414617 [TBL] [Abstract][Full Text] [Related]
7. BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia. Salesse S; Verfaillie CM Oncogene; 2002 Dec; 21(56):8547-59. PubMed ID: 12476301 [No Abstract] [Full Text] [Related]
8. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Hochhaus A; Kreil S; Corbin AS; La Rosée P; Müller MC; Lahaye T; Hanfstein B; Schoch C; Cross NC; Berger U; Gschaidmeier H; Druker BJ; Hehlmann R Leukemia; 2002 Nov; 16(11):2190-6. PubMed ID: 12399961 [TBL] [Abstract][Full Text] [Related]
9. [Analysis of ABL tyrosine kinase point mutations in imatinib treated chronic myelogenous leukemia patients]. Qin YZ; Liu YR; Li JL; Ruan GR; Zhu HH; Jiang Q; Fu JY; Lu Y; Chang Y; Li LD; Huang XJ; Chen SS; Qiu JY Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(45):3186-9. PubMed ID: 16405837 [TBL] [Abstract][Full Text] [Related]
10. Frequencies of the breakpoint cluster region types of the BCR/ABL fusion gene in Mexican Mestizo patients with chronic myelogenous leukemia. Ruiz-Argüelles GJ; Garcés-Eisele J; Reyes-Núñez V; Ruiz-Delgado GJ Rev Invest Clin; 2004; 56(5):605-8. PubMed ID: 15776864 [TBL] [Abstract][Full Text] [Related]
11. [Not just another kinase. New knowledge about myeloproliferative disease]. Bjerrum OW Ugeskr Laeger; 2006 Sep; 168(39):3293. PubMed ID: 17032590 [No Abstract] [Full Text] [Related]
12. [c-abl gene and bcr-abl fused gene in Ph1-positive leukemias]. Okabe M; Kunieda Y; Miyazaki T; Kakinuma M Nihon Rinsho; 1990 Aug; 48(8):89-97. PubMed ID: 2255098 [No Abstract] [Full Text] [Related]
13. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928 [TBL] [Abstract][Full Text] [Related]
14. Studying the pathogenesis of BCR-ABL+ leukemia in mice. Van Etten RA Oncogene; 2002 Dec; 21(56):8643-51. PubMed ID: 12476310 [TBL] [Abstract][Full Text] [Related]
15. [Molecular basis of chronic granulocytic leukemia: from test-tube to patient]. Skórski T Acta Haematol Pol; 1994; 25(2 Suppl 1):184-91. PubMed ID: 8067203 [TBL] [Abstract][Full Text] [Related]
16. P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia? Melo JV; Myint H; Galton DA; Goldman JM Leukemia; 1994 Jan; 8(1):208-11. PubMed ID: 8289491 [TBL] [Abstract][Full Text] [Related]
17. Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts. Deininger MW; Vieira SA; Parada Y; Banerji L; Lam EW; Peters G; Mahon FX; Köhler T; Goldman JM; Melo JV Cancer Res; 2001 Nov; 61(21):8005-13. PubMed ID: 11691826 [TBL] [Abstract][Full Text] [Related]